João Vitor Barboza Cardoso | Microbiology | Academic Molecular Biology Award

Published on by Molecular Biologist

Academic Molecular Biology Award

João Vitor Barboza Cardoso
Affiliation UFRGS
Country Brazil
Documents 48
Citations 1,240
h-index 18
Subject Area Microbiology
Event International Molecular Biologist Awards
ORCID
0000-0002-9878-280X

João Vitor Barboza Cardoso
UFRGS, China

João Vitor Barboza Cardoso is a Brazilian researcher affiliated with UFRGS, whose academic contributions in microbiology and molecular biology have been associated with interdisciplinary investigations involving microbial systems, molecular diagnostics, and translational biomedical research. His scientific profile demonstrates continued engagement in scholarly publication, collaborative research, and international academic dissemination within the biological sciences.[2]

Abstract

This article presents an overview of the academic and scientific profile of João Vitor Barboza Cardoso in the field of microbiology and molecular biology. The page summarizes institutional affiliations, research interests, scholarly output, publication impact, and relevance to international scientific recognition programs. The researcher’s contributions reflect active participation in molecular and biomedical investigations involving microbial mechanisms, laboratory methodologies, and translational scientific applications. The academic record demonstrates measurable citation performance and sustained engagement with contemporary microbiological research developments.[1]

Keywords

Microbiology; Molecular Biology; Biomedical Research; Molecular Diagnostics; Translational Science; Scientific Publications; Research Impact; Academic Recognition.

Introduction

Molecular biology and microbiology continue to represent central pillars of modern biomedical and life science research. Advancements in microbial genomics, cellular analysis, and molecular diagnostics have expanded scientific understanding across health, environmental, and translational disciplines. Researchers working in these areas contribute to the interpretation of complex biological systems through experimental methodologies and evidence-based scientific inquiry.[3]

João Vitor Barboza Cardoso has participated in this broader scientific landscape through academic investigations associated with microbiological and molecular approaches. His institutional activities at UFRGS align with the advancement of scientific research, publication dissemination, and collaborative academic engagement within the Brazilian and international research community.[2]

Research Profile

The academic profile of João Vitor Barboza Cardoso reflects sustained scholarly activity in microbiology-related research domains, including molecular characterization, laboratory investigation, and biomedical applications. His research record includes scientific publications indexed in international databases and collaborative studies contributing to contemporary biological science literature.

  • Institutional affiliation with UFRGS and participation in scientific research initiatives.
  • Research engagement within microbiology and molecular biology disciplines.
  • Publication activity in peer-reviewed scientific journals.
  • Citation impact reflecting scholarly visibility and academic dissemination.
  • Participation in interdisciplinary biomedical and molecular investigations.

Research Contributions

The research contributions associated with João Vitor Barboza Cardoso involve molecular and microbiological investigations supporting broader biomedical understanding. His scientific activities demonstrate alignment with evidence-based laboratory analysis, experimental methodologies, and publication dissemination within recognized scientific frameworks.

  1. Development and interpretation of molecular biology methodologies relevant to microbial and biomedical analysis.
  2. Participation in collaborative scientific studies involving microbiological systems and laboratory diagnostics.
  3. Contribution to scientific communication through publication in peer-reviewed journals and indexed databases.
  4. Support for translational biomedical research integrating molecular approaches and applied biological science.

Publications

The publication portfolio associated with João Vitor Barboza Cardoso includes scientific articles addressing microbiological and molecular biological subjects. Indexed publications contribute to academic visibility and demonstrate participation in ongoing scientific discussions within biomedical and life science research.

  • Peer-reviewed publications in microbiology and molecular biology.
  • Research dissemination through international academic databases.
  • Citation-indexed scholarly communication.
  • Scientific contributions linked to translational and laboratory-based biomedical research.

Representative DOI-linked scientific records further demonstrate the researcher’s visibility in indexed scientific ecosystems and digital citation networks.

Research Impact

Research impact indicators provide a measurable framework for evaluating scientific visibility, publication dissemination, and scholarly engagement. Citation metrics, h-index performance, and publication counts collectively reflect the degree to which scientific outputs contribute to ongoing academic discourse.[4]

The academic record attributed to João Vitor Barboza Cardoso demonstrates sustained participation in research communication and citation activity. Such indicators support recognition within academic evaluation frameworks and international award assessment criteria relevant to microbiology and molecular biology.[1]

Award Suitability

The International Molecular Biologist Awards recognize scientific contributions associated with molecular biology, microbiology, translational science, and biomedical innovation. Evaluation criteria commonly include publication quality, citation visibility, academic collaboration, and contributions to advancing scientific understanding within molecular and biological research domains.

Based on the documented academic profile, João Vitor Barboza Cardoso demonstrates characteristics associated with professional research achievement and scientific dissemination. His publication record, institutional affiliation, and research engagement support consideration within academic recognition and scientific distinction frameworks related to microbiology and molecular biology.[5]

Conclusion

João Vitor Barboza Cardoso represents an academic researcher engaged in microbiology and molecular biology through publication activity, collaborative research, and institutional scientific participation. His scholarly profile demonstrates measurable research visibility and contributions aligned with contemporary molecular and biomedical scientific inquiry. Continued research dissemination and interdisciplinary collaboration may further strengthen the long-term impact of his scientific work within the international research community.[1]

References

  1. ORCID. (n.d.). ORCID profile record for João Vitor Barboza Cardoso.
    https://orcid.org/0000-0002-9878-280X
  2. Madigan, M. T., et al. (2018). Brock Biology of Microorganisms. Pearson Education.
    https://doi.org/10.4324/9780429503788
  3. PubMed. (n.d.). Biomedical publication indexing database.
    https://pubmed.ncbi.nlm.nih.gov/
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Award evaluation and scientific recognition framework.
    https://molecularbiologist.org/

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.